‘Breakthrough’ breast cancer drugs get NHS approval
Two new “breakthrough” drugs to treat breast cancer have been given the green light for use on the NHS. The National Institute for Health and Care Excellence (NICE) approved palbociclib and ribociclib after negotiating prices for the treatments.
Research shows the drugs slow down advanced cancer for at least 10 months and can delay the need for chemotherapy. Around 8,000 people in England will now have access to the medications. There are about 45,000 new diagnoses of breast cancer in the country each year.
Palbociclib had earlier been rejected by NICE because of its high cost. Find out more BBC News